We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News and Perspectives |

Cardiovascular Death Risk Linked to Azithromycin Use

Bridget M. Kuehn
JAMA. 2012;307(22):2361. doi:10.1001/jama.2012.6421.
Text Size: A A A
Published online


Patients taking a 5-day course of the widely used drug azithromycin, commonly known as the “Z-Pak,” are at increased risk of death, according to a Food and Drug Administration (FDA) alert issued in mid May.

The alert was prompted by the publication of a study that found a small increased risk of cardiovascular death during the course of therapy with azithromycin (Ray WA et al. N Engl J Med. 2012;366[20]:1881-1890). The researchers compared short-term cardiac death rates among 3 groups: 347 795 individuals enrolled in Tennessee Medicaid who received prescriptions for azithromycin, more than 1 million propensity-matched controls not taking an antibiotic, and more than 1 million individuals who received prescriptions for amoxicillin or another antibiotic. Compared with individuals who took no antibiotics, those who took azithromycin had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% CI, 1.79-4.63). Individuals who took a 5-day course of azithromycin were also at elevated risk compared with those who took amoxicillin (hazard ratio, 2.49; 95% CI, 1.38-4.50). The authors estimate this would result in an additional 47 cardiovascular-related deaths per 1 million courses of azithromycin. They also said that the potential harm is even greater among patients who were already at elevated risk of cardiovascular adverse events, with azithromycin use associated with an estimated 245 cardiovascular deaths among such at-risk individuals.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles